Abstract:
This study was designed to discover filovirus entry inhibitors in a drug library of commercial medicines. One thousand and six hundred drugs were screened using the ZEBOV-GP/HIV model, a pseudovirus formed by an HIV-core packed with the Zaire Ebola virus glycoprotein. We identified 12 gonadal hormone drugs with inhibitory activities in ZEBOV-GP/HIV entry at final concentration of 10μmol·L
-1. Among them, three drugs exhibited strong activities with IC
50< 1μmol·L
-1, such as toremifene citrate(IC
50:0.19±0.02μmol·L
-1), tamoxifen citrate(IC
50:0.32±0.01μmol·L
-1) and clomiphene citrate(IC
50:0.53±0.02μmol·L
-1); seven drugs had moderate activities with IC
50 between 1 and 10μmol·L
-1, such as estradiol benzoate(IC
50:1.83±5.69μmol·L
-1), raloxifene hydrochloride(IC
50:3.48±0.07μmol·L
-1), equilin(IC
50:4.00±9.94μmol·L
-1), estradiol(IC
50:5.26±9.92μmol·L
-1), quinestrol(IC
50:6.36±5.37μmol·L
-1), estrone(IC
50:6.87±0.03μmol·L
-1) and finasteride(IC
50:9.94±0.45μmol·L
-1); two drugs, hexestrol(IC
50:14.20±0.55μmol·L
-1) and chlormadinone acetate(IC
50:24.60±0.36μmol·L
-1), had weak activities against ZEBOV. Further, toremifene citrate, tamoxifen citrate, clomiphene citrate, raloxifene hydrochloride and quinestrol could block both pseudovirus type Sudan ebola virus(SEBOV-GP/HIV) and Marburg virus(MARV-GP/HIV) entries.